CD22 and acute lymphoblastic leukemia: After analyzing the results of two pilot clinical trials (NCT02650414 and NCT02588456) using anti-CD22 CAR-T in six pediatric and three adult patients with R/R ALL, they found that response rates were unexpectedly lower compared with results from a similar trial at the National Cancer Institute (NCI) [11, 75].